With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
With shifting disease burdens, growing populations, and rising expectations comes a greater focus on value for money. International health funders and agencies want to know how to make the most of money spent by focusing on the highest impact interventions among the most affected populations. Whether through better procurement systems for health commodities, results-based financing, or more detailed assessments of the effective ness of health technology, CGD’s work aims to make health funding go further to save, prolong and improve more lives.
My colleague Scott Morris pointed out in a recent blog that the Global Fund to Fight AIDS, TB and Malaria will likely surpass the World Bank’s International Development Association (IDA) as the single largest foreign assistance contribution the United States makes to a multilateral institution. He described this move as “multilateralism-lite” – or a reliance on earmarking through multilateral channels by sector or country – and suggests this isn’t an optimal approach to poverty reduction and development.
It is a moral imperative that money spent on global health is used as effectively as possible to save lives, prevent and treat diseases, and reduce human suffering. While achieving more health for the money is the core business of all global health funders, the Global Fund to Fight AIDS, Tuberculosis and Malaria is particularly well placed to lead in this area because its New Funding Model makes possible the quick and flexible adoption of value for money principles and practices.
Join CGD on September 25th when Christoph Benn, Director of External Relations for the Global Fund, will discuss the Global Fund’s efforts to achieve more value for money and highlight the progress and potential of the New Funding Model. His remarks will be followed by a high-level panel discussion on the challenges and opportunities all global health funders face as they work to get the most return on their investments in health around the world. The discussion will be informed in part by recommendations from More Health for the Money, the forthcoming report of CGD’s Value for Money Working Group.
This is the data set for Policy Paper 31, in which Victoria Fan, Denizhan Duran, Rachel Silverman, and Amanda Glassman analyze data on the Global Fund performance-based financing system to test the association between grant ratings and disbursements.
This is the data set for Policy Paper 27 , “The Financial Flows of PEPFAR: A Profile,” in which Victoria Fan, Rachel Silverman, Denizhan Duran, and Amanda Glassman track the financial flows of the President's Emergency Plan for AIDS Relief (PEPFAR) from donor agencies via intermediaries and to prime partners.
As the largest bilateral donor in global health, the President’s Emergency Plan for AIDS Relief (PEPFAR) is unequaled in its reach and impact. Yet despite its larger-than-life profile, we’ve found that the details of its implementation arrangements and decision-making often remains obscure to the longstanding chagrin of globalhealthobservers. Among the common questions: Where does scarce PEPFAR funding go? Which countries and implementers receive the bulk of PEPFAR funds? And what factors influence PEPFAR’s allocation of resources across recipient countries?
Little is known about the President’s Emergency Plan for AIDS Relief (PEPFAR) financial flows within the United States (US) government, to its contractors, and to countries. We track the financial flows of PEPFAR – from donor agencies via intermediaries and finally to prime partners. We reviewed and analyzed publicly available government documents; a Center for Global Development dataset on 477 prime partners receiving PEPFAR funding in FY2008; and a cross-country dataset to predict PEPFAR outlays at the country level. We present patterns in Congressional appropriations to US government implementing agencies; the landscape of prime partners and contractors; and the allocation of PEPFAR funding by disease burden as a measure of country need.
In early 2006, CGD convened a working group–led by Ruth Levine- to address a pervasive problem in global health: poor forecasting of expected demand for key products. Long-term strategic demand forecasts are needed in order for manufacturers to make capacity investments, make more accurate long term plans for manufacturing and distribution, and for donors to conduct better multi-year program planning. Medium-term demand forecasts are equally essential. When such forecasts are off, manufacturers have to dispose of unsold drugs; donors and ministries of health may face uncertain prices and availability of essential products; and –most importantly- communities and individuals can face the terrible prospect of shortages, incomplete treatments and the emergence of drug resistance. The Wall Street Journal’s recent coverage of shortages of pediatric tuberculosis (TB) treatments demonstrates the weaknesses –or perhaps absence- of adequate demand forecasting in India’s anti-TB programs.
Following the launch of the More Health for the Money consultation draft, Amanda Glassman and Victoria Fan host a Twitter chat to answer questions, receive comments and criticisms, and discuss some their findings and recommendations. The Twitter chat will occur on Thursday, June 12 at 2 p.m. ET.
Use and follow: #valueformoney
Fielding questions and comments:
Amanda Glassman (@glassmanamanda) is a senior fellow and leads the Global Health Policy team at the Center for Global Development. Her research includes work on priority-setting, resource allocation and value for money in global health, with a particular interest in vaccination.
Victoria Fan (@FanVictoria) is a research fellow at the Center for Global Development. Her research focuses on the design and evaluation of health policies and programs. Fan joined the Center after completing her doctorate at Harvard School of Public Health where she wrote her dissertation on health systems in India.